You are here

  • Home
  • Archive
  • Volume 84, Issue 11
  • EFFICACY AND SAFETY OF NATALIZUMAB TREATMENT FOR RELAPSING–REMITTING MULTIPLE SCLEROSIS: INTERIM RESULTS OF THE TYSABRI® OBSERVATIONAL PROGRAMME IN THE UK

Article info

Article menu
Download PDFPDF
Association of British Neurologists (ABN) joint meeting with the Royal College of Physicians (RCP), London, 23–24 October 2013
179
EFFICACY AND SAFETY OF NATALIZUMAB TREATMENT FOR RELAPSING–REMITTING MULTIPLE SCLEROSIS: INTERIM RESULTS OF THE TYSABRI® OBSERVATIONAL PROGRAMME IN THE UK

Authors

    Citation

    Hanna J, Rosen JP, Smethurst C
    EFFICACY AND SAFETY OF NATALIZUMAB TREATMENT FOR RELAPSING–REMITTING MULTIPLE SCLEROSIS: INTERIM RESULTS OF THE TYSABRI® OBSERVATIONAL PROGRAMME IN THE UK
    Journal of Neurology, Neurosurgery & Psychiatry 2013;84:e2.

    Publication history

    • First published October 9, 2013.
    Online issue publication 
    April 05, 2017

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information

    Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions